News stories about EpiCept (NASDAQ:IMNP) have been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EpiCept earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.7124843609837 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
IMNP has been the topic of several research reports. ValuEngine raised shares of EpiCept from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Maxim Group started coverage on shares of EpiCept in a research note on Friday, January 5th. They issued a “buy” rating and a $3.00 target price for the company.
NASDAQ:IMNP opened at $0.33 on Friday. EpiCept has a 12 month low of $0.31 and a 12 month high of $5.02. The company has a current ratio of 0.03, a quick ratio of 0.03 and a debt-to-equity ratio of 3.04.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/immune-pharmaceuticals-imnp-receiving-somewhat-favorable-media-coverage-analysis-shows.html.
Immune Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases.
Receive News & Ratings for EpiCept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EpiCept and related companies with MarketBeat.com's FREE daily email newsletter.